Virus-like particles and methods of production thereof
AssigneeUniversity of Dundee
InventorJohn FOERSTER
Life of this patent
Estimating the term…
Abstract
The present invention relates to virus-like particles (VLPs) having a high affinity protein attachment system which allows interchangeable decoration with any functional molecule of choice. The present invention further relates to processes of producing the VLPs, including a rapid single cell process, and uses of the VLPs in research, diagnosis and as vaccines for use in prevention/treatment of diseases.
Claims39
A virus-like particle (VLP) comprising:
- One or more hepatitis B capsid proteins
- One or more pairs of binding proteins, each pair of binding proteins comprising a first binding protein and a second binding protein, wherein the pair of binding proteins comprises a bacterial toxin and its inhibitor
- One or more functional molecules
- wherein each hepatitis B capsid protein is attached to a first binding protein, wherein each functional molecule is attached to a second binding protein, and wherein the first and second binding proteins are bound to each other.
A VLP according to any preceding claim, wherein each functional molecule may be the same or different, preferably wherein the functional molecule is selected from:
- a protein or non-protein antigen or an epitope thereof, an antigen binding protein, or a flourescent molecule.
A virus-like particle (VLP) comprising:
- One or more viral capsid proteins
- One or more first binding proteins comprising a chemical modification, wherein each first binding protein is a bacterial toxin inhibitor;
- One or more functional molecules
- wherein each viral capsid protein is attached to a first binding protein, and wherein each chemical modification is attached to a functional molecule.
A VLP according to any preceding claim, wherein the bacterial toxin inhibitor is selected from Im7, Im8, Im9, Im2, and Barstar.
A capsid fusion protein comprising a viral capsid protein fused to a binding protein, wherein the binding protein is a bacterial toxin inhibitor.
A functional fusion protein comprising a functional molecule fused to a binding protein wherein the binding protein is a bacterial toxin.
A functional fusion protein comprising a first binding protein fused to a further binding protein, wherein the first binding protein is a bacterial toxin, and the further binding protein is able to bind to functional molecules that are antigen binding proteins.
A host cell comprising one or more vectors, the one or more vectors comprising a first nucleic acid encoding a hepatitis B capsid protein attached to a first binding protein;
- and a second nucleic acid encoding a functional molecule attached to a second binding protein;
- wherein the first and second binding proteins are capable of binding to each other.
A host cell comprising one or more vectors, the one or more vectors comprising a first nucleic acid encoding a viral capsid protein attached to a first binding protein;
- and a second nucleic acid encoding a functional molecule;
- wherein the functional molecule is capable of binding to the first binding protein via a chemical modification of the first binding protein.
A process of producing a virus-like particle (VLP) in a single host cell comprising:
- (a) Providing a host cell comprising one or more vectors, wherein the one or more vectors comprise:
- (i) a first nucleic acid encoding a viral capsid protein attached to a first binding protein;
- and
- (ii) (a) a second nucleic acid encoding a functional molecule optionally attached to a second binding protein;
- and/or
- (b) a third nucleic acid encoding a second binding protein attached to a third binding protein;
- (b) Culturing the host cell under conditions to express the proteins from the first, second and/or third nucleic acids respectively;
- (c) Forming virus-like particles from the proteins.
A process of producing a virus-like particle (VLP), comprising;
- (a) Providing a first host cell comprising one or more vectors, wherein the one or more vectors comprise:
- (i) a first nucleic acid encoding a hepatitis B capsid protein attached to a first binding protein, wherein the first binding protein is a bacterial toxin inhibitor;
- (b) Providing a one or more further host cell(s) comprising one or more vectors, wherein the one or more vectors comprise:
- a second nucleic acid encoding a functional molecule optionally attached to a second binding protein, wherein the second binding protein is a bacterial toxin;
- and/or
- (ii) a third nucleic acid encoding a second binding protein attached to a third binding protein, wherein the second binding protein is a bacterial toxin;
- (c) Culturing the host cells under conditions to express the proteins from the first, second and/or third nucleic acids respectively;
- (d) Recovering the proteins;
- (e) Mixing the proteins to form virus-like particles.
Dependencies are inferred from the claim text.